Sinovac's phase 3 clinical trial show mixed result in different countries: 65% in Indonesia, 91.25% in Turkey, 50.4% in Brazil. Let's see more of the real world result. Although the Indonesian health worker in the study were fully inoculated, but as front line health worker, they're directly exposed to infected patient daily instead of living in a relatively isolated Brazilian town Serrana.China's Sinovac Covid-19 vaccine found highly effective in real world study
Updated May 12, 2021, 2:47 pm
JAKARTA (BLOOMBERG) - Sinovac Biotech Ltd's vaccine is wiping out Covid-19 among health workers in Indonesia, an encouraging sign for the dozens of developing countries reliant on the controversial Chinese shot, which performed far worse than Western vaccines in clinical trials.
Indonesia tracked 25,374 health workers in capital city Jakarta for 28 days after they received their second dose and found that the vaccine protected 100 per cent of them from death and 96 per cent from hospitalisation as soon as seven days after, said Health Minister Budi Gunadi Sadikin in an interview on Tuesday (May 11). The workers were tracked until late February.
Mr Sadikin also said that 94 per cent of the workers had been protected against infection - an extraordinary result that goes beyond what was measured in the shot's numerous clinical trials - though it's unclear if the workers were uniformly screened to detect asymptomatic carriers.
"We see a very, very drastic drop," in hospitalisations and deaths among medical workers, Mr Sadikin said.
It's not known what strain of the coronavirus Sinovac's shot worked against in Indonesia, but the country has not flagged any major outbreaks driven by variants of concern.
A spokesman for Sinovac in Beijing said the company cannot comment on the Indonesian study until it acquires more details.
In a separate interview with Bloomberg on Tuesday, Sinovac's chief executive officer Yin Weidong defended the disparity in clinical data around the shot, and said there was growing evidence CoronaVac is performing better when applied in the real world.
But the real-world examples also show that the Sinovac shot's ability to quell outbreaks requires the vast majority of people to be vaccinated, a scenario that developing countries with poor health infrastructure and limited access to shots cannot reach quickly.
In the Indonesian health worker study, and another in a Brazilian town of 45,000 people called Serrana, nearly 100 per cent of people studied were fully vaccinated, with serious illness and deaths dropping after they were inoculated.
..........
